NORTH CHICAGO, Ill., Feb. 3, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced financial results for the fourth quarter and full year ended December 31, 2020.

IRVINE, Calif., Jan. 26, 2021 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the launch of CoolSculpting^® Elite, its next generation fat reduction system with applicators designed to complement the body's natural curves. CoolSculpting^® Elite harnesses proven CoolSculpting^® technology to target, freeze, and eliminate treated fat cells. CoolSculpting^® Elite is FDA cleared to treat visible fat bulges in nine areas of the body including the thigh, abdomen, and flank, along with bra fat, back fat, underneath the buttocks (also known as banana roll), upper arm, and the submental and submandibular areas.

NORTH CHICAGO, Ill., Jan. 25, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV), today announced that the European Commission (EC) has approved RINVOQTM (upadacitinib, 15 mg), an oral, once daily selective and reversible JAK inhibitor for the treatment of active psoriatic arthritis (PsA) in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. RINVOQ may be used as monotherapy or in combination with methotrexate. RINVOQ is also indicated for the treatment of active ankylosing spondylitis (AS) in adult patients who have responded inadequately to conventional therapy.¹ The EC approval is supported by data from the three pivotal clinical trials SELECT-PsA 1, SELECT-PsA 2 and SELECT-AXIS 1, demonstrating RINVOQ's efficacy across multiple measures of disease activity.* ^4-6

NORTH CHICAGO, Ill., Jan. 15, 2021 /PRNewswire/ -- Allergan Aesthetics and Allergan, an AbbVie company (NYSE: ABBV), announced today that scientific and clinical experts in the field of neurotoxins will present results from 16 abstracts spanning pre-clinical and clinical studies evaluating key safety and efficacy of BOTOX® (onabotulinumtoxinA) across multiple therapeutic and cosmetic indications. Data includes long-term immunogenicity rates across 10 therapeutic and aesthetic indications, analyses from the Adult Spasticity International Registry (ASPIRE) study and Cervical Dystonia Patient Registry for BOTOX® Efficacy (CD-PROBE), reviewing adherence to onabotulinumtoxinA treatment in patients with spasticity and efficacy and tolerability in patients with cervical dystonia, respectively. Also to be presented are data on incontinence product use and associated costs in patients with overactive bladder treated with onabotulinumtoxinA. Additionally, results from a randomized controlled clinical trial on the efficacy and safety of three active doses of onabotulinumtoxinA for the treatment of neurogenic detrusor overactivity in children and findings from a study on the safety, pharmacodynamic response and treatment satisfaction, with increasing doses of onabotulinumtoxinA in patients with moderate to severe dynamic glabellar lines will be presented. These data will be presented at the TOXINS 2021 Virtual Conference, organized by The International Neurotoxin Association (INA), January 16-17.

IRVINE, Calif., Jan. 12, 2021 /PRNewswire/ -- Today Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced that it has entered into a warrant agreement with Cypris Medical, a privately held, medical device company based in Chicago. Following the completion of a clinical trial to be initiated in 2021, Allergan Aesthetics will have the right to exercise an option to acquire Cypris Medical, including the company's Xact device. The planned clinical trial will evaluate the safety and effectiveness of Xact in treating midface descent as well as for neck lifts.

NORTH CHICAGO, Ill., Jan. 12, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its fourth-quarter and full-year 2020 financial results on Wednesday, February 3, 2021, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website investors.abbvie.com. An archived edition of the session will be available later that day.

NORTH CHICAGO, Ill., Jan. 7, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive results from two Phase 3 induction studies, ADVANCE and MOTIVATE, showing both doses of risankizumab (600 mg and 1200 mg) met both primary endpoints of clinical remission and endoscopic response at week 12 in adult patients with moderate to severe Crohn's disease.^1,2 The ADVANCE study enrolled patients who had an inadequate response or were intolerant to conventional and/or biologic therapy.¹ The MOTIVATE study evaluated patients who had responded inadequately or were intolerant to biologic therapy.²

NORTH CHICAGO, Ill., Jan. 6, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the 39^th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021. Members of AbbVie's executive leadership team will present virtually at 3:30 p.m. Central time, including Richard A. Gonzalez, chairman of the board and chief executive officer, Michael Severino, M.D., vice chairman and president, Robert A. Michael, executive vice president and chief financial officer, and Jeffrey R. Stewart, executive vice president, commercial operations.

NORTH CHICAGO, Ill., Jan. 5, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive top-line results from two Phase 3 studies in adults with active psoriatic arthritis, KEEPsAKE-1 and KEEPsAKE-2, showing that significantly more patients treated with risankizumab (150 mg) achieved the primary endpoint of ACR20 response at week 24 versus placebo.¹ In KEEPsAKE-1 and KEEPsAKE-2, 57 and 51 percent of patients receiving risankizumab achieved ACR20 response at week 24, respectively, versus 34 and 27 percent receiving placebo (p<0.001).¹